Our results demonstrate the efficacy of high-throughput sequencing technology in genetic testing of neonates suspected with congenital TTP and have revealed a novel compound missense mutation in ADAMTS13 that has not been reported in China or elsewhere. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.